人用联合疫苗市场按产品类型、年龄层、联合类型、通路和地区划分

预计到 2026 年，人类结合疫苗市场价值将达到 110 亿美元，到 2033 年将达到 201 亿美元，2026 年至 2033 年的年复合成长率（CAGR）为 9%。

由于在儿童免疫和老年预防保健领域的应用不断扩展，人源结合疫苗市场正经历显着成长。此外，生物製药研究的拓展、mRNA多价技术的突破以及复杂製剂监管标准的加强，预计将在预测期内推动市场成长。抗原是疫苗的基本结构成分。结合疫苗检测是製药、生物分析和临床产业常用的研发技术。人源结合疫苗只需单次注射即可提供多种病原体的定性和定量保护，有助于实现精准免疫并提高患者依从性。

人类结合疫苗产业正经历创新时期，这得益于许多先进分析技术和精密递送系统的应用，以及公共卫生、旅游医学、生物技术和临床诊断等各领域对特定生化分析的高需求。这些发展正在透过扩大人类结合疫苗的产能、提高稳定性和安全性以及提升生产自动化程度变革时期市场格局。

市场动态

受製药和生技产业对高效免疫和多价预防的高需求驱动，人源结合疫苗市场正经历强劲成长。抗原和佐剂在疫苗研发、品管和免疫反应检验中发挥关键作用。准确测定抗原和佐剂的含量并了解其协同效应至关重要。随着製药业将重点放在六价疫苗和基于mRNA的多价平台等复杂生物製药上，深入研究抗原干扰的细节将有助于确保这些复杂药物的有效性、安全性和稳定性。

人源结合疫苗在临床诊断和公共卫生计画中的日益普及是推动这一市场趋势的主要因素。在临床诊断中，将多种抗原结合到单次注射中，对于保护和监测易感人群免受白喉、百日咳和乙型肝炎等感染疾病至关重要。新技术提高了疫苗的稳定性和有效性，使医生能够利用即时流行病学数据制定个人化的疫苗接种方案。

此外，全球感染疾病率的上升显着加速了对人用结合疫苗的需求，因为这些产品在感染疾病的预防和控制中发挥着至关重要的作用。包括流感、呼吸道合胞病毒（RSV）和新冠肺炎（COVID-19）在内的传染病通常需要精确的多价疫苗分析，以监测群体免疫并指导治疗性介入。

mRNA技术在人类结合疫苗中的应用标誌着分析和保护能力的重大转折点。新一代平台能够以卓越的特异性和灵敏度同时递送多种抗原。这些系统采用先进的脂质奈米颗粒（LNP）标靶化技术，即使在复杂的全球卫生环境下，也能以最少的物流设置实现快速生产和精准标靶化。

本次调查的主要特点

• 本报告对人类结合疫苗市场进行了详细分析，以 2025 年为基准年，给出了预测期（2026-2033 年）内的市场规模（十亿美元）和復合年增长率（%）。
• 该报告还重点介绍了各个细分市场的潜在商机，并概述了该市场具有吸引力的投资提案矩阵。
• 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要参与者采取的竞争策略的重要见解。
• 根据以下参数对人类结合疫苗市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告的研究结果将使负责人和企业经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 人类结合疫苗市场报告涵盖了该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 相关人员可以透过各种用于分析人类结合疫苗市场的策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

• 调查目的
• 先决条件
• 简称

第二章 市场范围

• 报告概述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监理及趋势分析

• 市场动态
  • 司机
  • 抑制因素
  • 市场机会
• 影响分析
• 近期产品发布
• 流行病学
• 合併、收购和合作
• 法规环境
• 重大进展
• PEST分析
• 伙伴关係情景
• 品牌和价格分析
• 经销商状态
• 波特分析
• 技术进步
• 重大进展
• 市场趋势
• 前景
• 按销售额排名的主要企业

4. 2026-2033年全球人用结合疫苗市场（依产品类型划分）

• 灭活疫苗
• 减毒活病毒疫苗

5. 2026-2033年全球人用结合疫苗市场（依年龄层划分）

• 儿童
• 成人

6. 2026-2033年全球人用联合疫苗市场（以联合类型划分）

• DTaP/IPV/B型肝炎疫苗
• DTaP/Hib/IPV
• MMR II
• 乙型肝炎/Hib
• 其他的

7. 2026-2033年全球人用结合疫苗市场（依通路划分）

• 医院药房
• 零售药房
• 网路药房

8. 2026-2033年全球人用结合疫苗市场（按地区划分）

• 北美洲
  • 介绍
  • 按产品类型分類的市场规模、预测及年增长率（2026-2033年）
  • 市场规模及预测、年增长率（按年龄组别划分）
  • 按组合类型分類的市场规模和预测，以及年成长率
  • 市场规模及预测、年成长率（依通路划分）
  • 市场规模及预测、年增速（依国家/地区划分）
    • 我们
    • 加拿大
• 拉丁美洲
  • 介绍
  • 按产品类型分類的市场规模、预测及年增长率（2026-2033年）
  • 市场规模及预测、年增长率（按年龄组别划分）
  • 按组合类型分類的市场规模和预测，以及年成长率
  • 市场规模及预测、年成长率（依通路划分）
  • 市场规模及预测、年增速（依国家/地区划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲国家
• 欧洲
  • 介绍
  • 按产品类型分類的市场规模、预测及年增长率（2026-2033年）
  • 市场规模及预测、年增长率（按年龄组别划分）
  • 按组合类型分類的市场规模和预测，以及年成长率
  • 市场规模及预测、年成长率（依通路划分）
  • 市场规模及预测、年增速（依国家/地区划分）
    • 英国
    • 德国
    • 义大利
    • 法国
    • 西班牙
    • 俄罗斯
    • 比荷卢经济联盟
    • 丹麦
    • 挪威
    • 瑞典
    • 其他欧洲
• 亚太地区
  • 介绍
  • 按产品类型分類的市场规模、预测及年增长率（2026-2033年）
  • 市场规模及预测、年增长率（按年龄组别划分）
  • 按组合类型分類的市场规模和预测，以及年成长率
  • 市场规模及预测、年成长率（依通路划分）
  • 市场规模及预测、年增速（依国家/地区划分）
    • 中国
    • 台湾
    • 印度
    • 日本
    • 印尼
    • 马来西亚
    • 菲律宾
    • 新加坡
    • 澳洲
    • 韩国
    • 亚太其他地区
• 中东和非洲
  • 介绍
  • 按产品类型分類的市场规模、预测及年增长率（2026-2033年）
  • 市场规模及预测、年增长率（按年龄组别划分）
  • 按组合类型分類的市场规模和预测，以及年成长率
  • 市场规模及预测、年成长率（依通路划分）
  • 市场规模及预测、年增速（依国家/地区划分）
    • 巴林
    • 科威特
    • 阿曼
    • 卡达
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 南非
    • 北非
    • 中非
    • 其他中东国家

第九章 竞争情势

• Sanofi
• Pfizer Inc.
• Cadila Healthcare Ltd.
• GlaxoSmithKline plc, CSL Ltd.
• Mitsubishi Tanabe Pharma Corp.
• Daiichi Sankyo Company Limited
• Merck &Co.
• Mass Biologics
• Meiji Holdings Co. Ltd.
• Serum Institute of India
• Moderna
• AstraZeneca
• Influvac
• Biological
• PaxVax Corporation
• Emergent BioSolutions Inc.
• CNBG
• Takeda Pharmaceutical Co. Ltd.
• NPS MedicineWise

第十章各节

• 调查方法
• 关于本公司

Human Combination Vaccines Market is estimated to be valued at USD 11 Bn in 2026 and is expected to reach USD 20.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9% from 2026 to 2033.

The human combination vaccines market is advancing significantly with rising applications in pediatric immunization and geriatric preventative care. Moreover, expanding biopharmaceutical research, breakthroughs in mRNA multivalent technology, and tightening regulatory standards for complex formulations are expected to drive market growth over the forecast period. Antigens are the basic structural components of vaccines. Combination vaccine analysis is a commonly used development technique in pharmaceutical, bioanalytical, and clinical industries. Human combination vaccines are utilized for qualitative as well as quantitative protection against multiple pathogens in a single injection, which aids in accurate immunization and improved patient compliance.

The human combination vaccines industry is having a revolutionary period bolstered by a number of advancing analytical factors and the adoption of sophisticated delivery systems, along with high demand for particular biochemical analysis in different sectors, including public health, travel medicine, biotechnology, and clinical diagnostics. These developments have expanded the capabilities of human combination vaccines and enhanced their stability and safety profiles, as well as manufacturing automation, marking a transformative phase in the market.

Market Dynamics

The human combination vaccines market is experiencing robust growth fueled by the high demand for streamlined immunization and multivalent prevention within pharmaceutical and biotechnology industries. Antigens and adjuvants play a crucial role in vaccine development, quality control, and checking how immunological responses are working. It is essential to measure them accurately and understand their synergistic effects. As the pharmaceutical industry focuses more on complex biologic solutions like hexavalent shots and mRNA-based multivalent platforms, studying the details of antigenic interference helps ensure these complex drugs are effective, safe, and stable.

The expanding utilization of human combination vaccines in clinical diagnostics and public health initiatives is significantly contributing to the evolving dynamics of the human combination vaccines market. In clinical diagnostics, these formulations play a major role in protecting and monitoring vulnerable populations against infectious diseases like diphtheria, pertussis, and hepatitis B by consolidating multiple antigens into a single injection dose. The novel technology has made these vaccines more stable and effective, allowing doctors to create personalized immunization plans using real-time epidemiological data.

In addition, the rising incidence of infectious diseases worldwide is majorly speeding up the demand for human combination vaccines, as these products play a critical role in the prevention and management of such conditions. Communicable diseases, including influenza, RSV and COVID-19 usually require precise multivalent profiling to monitor population-wide immunity and guide therapeutic interventions.

The application of mRNA technology in human combination vaccines represents a significant shift in analytical and preventative capabilities. Next-generation platforms now allow for the simultaneous delivery of multiple antigens with remarkable specificity and sensitivity. These systems utilize advanced lipid nanoparticle (LNP) targeting, allowing for precise targeting as well as rapid manufacturing even in complex global health landscapes with minimal logistical preparation.

Key Features of the Study

• This report provides in-depth analysis of the human combination vaccines market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the human combination vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi, Pfizer Inc., Cadila Healthcare Ltd., GlaxoSmithKline plc, CSL Ltd., Mitsubishi Tanabe Pharma Corp., Daiichi Sankyo Company, Limited, Merck & Co., Crunchbase Inc., Mass Biologics, Meiji Holdings Co. Ltd., Serum Institute of India, Moderna, AstraZeneca, Influvac, Biological, PaxVax Corporation, Emergent BioSolutions Inc., CNBG, Takeda Pharmaceutical Co. Ltd., and NPS MedicineWise
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The human combination vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the human combination vaccines market

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2026 - 2033)
  • Inactivated vaccine
  • Live attenuated vaccine
• Age Group Insights (Revenue, USD Bn, 2026 - 2033)
  • Children
  • Adults
• Combination Type Insights (Revenue, USD Bn, 2026 - 2033)
  • DTaP/IPV/Hep B
  • DTaP/Hib/IPV
  • MMR II
  • Hep B-Hib
  • Others
• Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Italy
  • France
  • Russia
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa
• Key Players Insights
  • Sanofi
  • Pfizer Inc.
  • Cadila Healthcare Ltd.
  • GlaxoSmithKline plc
  • CSL Ltd.
  • Mitsubishi Tanabe Pharma Corp.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Merck & Co.,
  • Crunchbase Inc.
  • Mass Biologics
  • Meiji Holdings Co. Ltd
  • Serum Institute of India Moderna
  • Astrazeneca
  • Influvac
  • Biological
  • PaxVax Corporation
  • Emergent BioSolutions Inc
  • CNBG
  • Takeda Pharmaceutical Co. Ltd.
  • NPS MedicineWise

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaboration
• Regulatory Scenario
• Key Developments
• PEST Analysis
• Partnership Scenario
• Brand and Pricing Analysis
• Distributors Landscape
• Porters Analysis
• Technological Advancements
• Key Developments
• Market Trend
• Future Prospective
• Top Market Players by Revenue

4. Human Combination Vaccines Market By Product Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Inactivated vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Live attenuated vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

5. Human Combination Vaccines Market By Age Group, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

6. Human Combination Vaccines Market By Combination Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• DTaP/IPV/Hep B
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• DTaP/Hib/IPV
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• MMR II
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Hep B-Hib
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

7. Human Combination Vaccines Market By Distribution Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Retailer Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

8. Human Combination Vaccines Market By Region, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, en2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Benelux
    • Denmark
    • Norway
    • Sweden
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • China
    • Taiwan
    • India
    • Japan
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Combination Type, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • Bahrain
    • Kuwait
    • Oman
    • Qatar
    • Saudi Arabia
    • UAE
    • Israel
    • South Africa
    • North Africa
    • Central Africa
    • Rest of the Middle East

9. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cadila Healthcare Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GlaxoSmithKline plc, CSL Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mitsubishi Tanabe Pharma Corp.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Daiichi Sankyo Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mass Biologics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Meiji Holdings Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Serum Institute of India
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Moderna
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Influvac
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biological
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• PaxVax Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Emergent BioSolutions Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CNBG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Takeda Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• NPS MedicineWise
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us